Traditional chemotherapy still gold standard over new targeted therapy for HER2-positive breast cancers
University of California, Los Angeles (UCLA), Health SciencesResults of a phase 3 clinical trial by researchers at UCLA’s Jonsson Comprehensive Cancer Center found that women with HER2-positive breast cancer had significantly better response rates, but more severe side effects, when they were treated with traditional neoadjuvant chemotherapy along with dual HER2-targeted blockade, compared to a more novel approach using HER2-targeted chemotherapy plus HER2-targeted blockade.